TY - JOUR
T1 - Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia
T2 - A pilot study
AU - Cervellati, Carlo
AU - Trentini, Alessandro
AU - Romani, Arianna
AU - Bellini, Tiziana
AU - Bosi, Cristina
AU - Ortolani, Beatrice
AU - Zurlo, Amedeo
AU - Passaro, Angelina
AU - Seripa, Davide
AU - Zuliani, Giovanni
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Converging lines of evidence suggest that paraoxonase-1 (PON-1) may confer protection against inflammatory and oxidative challenge which, in turn, plays a key-role in the onset and progression of dementia. The aim of this study was to evaluate whether serum PON-1 paraoxonase/arylesterase activities might predict the clinical conversion of mild cognitive impairment (MCI) to late-onset Alzheimer's disease (LOAD) or vascular dementia (VAD). Serum paraoxonase and arylesterase activities were measured by spectrophotometric assays at baseline in 141 MCI patients (median age: 77 years; interquartile range 71-81) and in 78 healthy controls (median age: 76 years; interquartile range 73-79). After 2 years of follow-up, 86 MCI remained stable (MCI/MCI), 34 converted to LOAD (MCI/LOAD), whereas 21 converted to VAD (MCI/VAD). Baseline arylesterase activity was lower in all MCI groups compared with controls (all p <0.01), whereas paraoxonase activity was lower in MCI/VAD group compared to controls (p <0.05) and MCI/MCI patients (p = 0.009). Low paraoxonase and arylesterase activities (I quartile) were associated to higher risk of conversion to VAD (OR: 3.74, 95% CI: 1.37-10.25 and OR: 3.16, 95% CI: 1.17-8.56, respectively). Our results suggest that in MCI patients low PON-1 activity might contribute to identify individuals susceptible to develop vascular dementia.
AB - Converging lines of evidence suggest that paraoxonase-1 (PON-1) may confer protection against inflammatory and oxidative challenge which, in turn, plays a key-role in the onset and progression of dementia. The aim of this study was to evaluate whether serum PON-1 paraoxonase/arylesterase activities might predict the clinical conversion of mild cognitive impairment (MCI) to late-onset Alzheimer's disease (LOAD) or vascular dementia (VAD). Serum paraoxonase and arylesterase activities were measured by spectrophotometric assays at baseline in 141 MCI patients (median age: 77 years; interquartile range 71-81) and in 78 healthy controls (median age: 76 years; interquartile range 73-79). After 2 years of follow-up, 86 MCI remained stable (MCI/MCI), 34 converted to LOAD (MCI/LOAD), whereas 21 converted to VAD (MCI/VAD). Baseline arylesterase activity was lower in all MCI groups compared with controls (all p <0.01), whereas paraoxonase activity was lower in MCI/VAD group compared to controls (p <0.05) and MCI/MCI patients (p = 0.009). Low paraoxonase and arylesterase activities (I quartile) were associated to higher risk of conversion to VAD (OR: 3.74, 95% CI: 1.37-10.25 and OR: 3.16, 95% CI: 1.17-8.56, respectively). Our results suggest that in MCI patients low PON-1 activity might contribute to identify individuals susceptible to develop vascular dementia.
KW - Alzheimer's disease
KW - arylesterase activity
KW - mild cognitive impairment
KW - paraoxonase activity
KW - paraoxonase-1
KW - vascular dementia
UR - http://www.scopus.com/inward/record.url?scp=84943580041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943580041&partnerID=8YFLogxK
U2 - 10.1111/jnc.13240
DO - 10.1111/jnc.13240
M3 - Article
C2 - 26178739
AN - SCOPUS:84943580041
VL - 135
SP - 395
EP - 401
JO - Journal of Neurochemistry
JF - Journal of Neurochemistry
SN - 0022-3042
IS - 2
ER -